[
  {
    "ts": "2026-02-17T11:59:00+00:00",
    "headline": "U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma",
    "summary": "PRINCETON, N.J., February 17, 2026--U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or Refractory Multiple Myeloma",
    "url": "https://finance.yahoo.com/news/u-food-drug-administration-accepts-115900945.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "5b03cb8f-4bdb-3319-ad90-34193a38c02c",
      "content": {
        "id": "5b03cb8f-4bdb-3319-ad90-34193a38c02c",
        "contentType": "STORY",
        "title": "U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma",
        "description": "",
        "summary": "PRINCETON, N.J., February 17, 2026--U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or Refractory Multiple Myeloma",
        "pubDate": "2026-02-17T11:59:00Z",
        "displayTime": "2026-02-17T11:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/24c605839825700064bf4f7f09e7424f",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3KB.9pDr3lwH6hkTZRngwA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/24c605839825700064bf4f7f09e7424f.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/it_Tr6gW0lyWzSuhJW0aCA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/24c605839825700064bf4f7f09e7424f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/u-food-drug-administration-accepts-115900945.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/u-food-drug-administration-accepts-115900945.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T15:00:00+00:00",
    "headline": "Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?",
    "summary": "BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.",
    "url": "https://finance.yahoo.com/news/bmys-growth-portfolio-counter-legacy-150000302.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "65d09168-aae6-38fe-90bd-a233a8b01f29",
      "content": {
        "id": "65d09168-aae6-38fe-90bd-a233a8b01f29",
        "contentType": "STORY",
        "title": "Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?",
        "description": "",
        "summary": "BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.",
        "pubDate": "2026-02-17T15:00:00Z",
        "displayTime": "2026-02-17T15:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bmys-growth-portfolio-counter-legacy-150000302.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bmys-growth-portfolio-counter-legacy-150000302.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]